18 Doctor-Authored Studies & Papers Proving Peptide Mechanisms

BPC-157 directly stimulates focal adhesion kinase (FAK) and paxillin phosphorylation via early growth response protein-1 (Egr-1). Phosphorylates VEGFR2 without oncogenic cell proliferation, triggering rapid collateral microvascular angiogenesis, promoting tenocyte cell migration into defect gaps, and reversing corticosteroid-impaired collagen remodeling.

GHK-Cu remodels human genomic expression: down-regulates 1,084 genes and up-regulates 1,123 human genes. Directly enhances mRNA for collagen types I, III, IV, decorin, and tropoelastin while up-regulating copper/zinc superoxide dismutase (SOD1). Concurrently suppresses TGF-beta-driven fibrotic scarring and blocks NF-kappa-B inflammatory cascade transcription.

Serves as the principal eukaryotic monomeric G-actin sequestering peptide (binding affinity Kd ≈ 1 μM). Prevents premature actin polymerization while feeding actin subunits directly to lamellipodia and filopodia for cell locomotion. Activates integrin-linked kinase (ILK), up-regulates vascular endothelial growth factor (VEGF), and accelerates matrix metalloproteinase-2 (MMP-2) remodeling without hypertrophic fibrosis.

CJC-1295 binds anterior pituitary GHRH receptors, stimulating adenylate cyclase and cAMP release. Clinical human pharmacokinetic evaluation revealed 2- to 10-fold increases in GH area under the curve and a 1.5- to 3-fold sustained increase in plasma IGF-1 without loss of pituitary pulsatility, proving that hypothalamic somatostatin control mechanisms remain intact.

Tesamorelin (trans-3-hexenoyl GHRH) is an engineered 44-amino-acid peptide with superior enzymatic resistance to DPP-4. In a landmark 412-patient Phase 3 NEJM clinical trial, it stimulated physiologic pulsatile GH release, causing selective lipolysis of visceral adipose tissue (VAT) and significant triglyceride reduction without deteriorating glucose parameters or peripheral insulin sensitivity.

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. It acts as an exercise mimetic by inhibiting the folate-methionine cycle, thereby elevating endogenous AICAR and directly phosphorylating AMP-activated protein kinase (AMPK). Mobilizes GLUT4 glucose transporters in skeletal muscle tissue entirely independent of insulin signaling.

Uniquely combines potent, balanced agonism at three distinct GPCRs: GLP-1R (gut motility & satiety), GIP-R (insulin sensitivity and adipose lipid buffering), and GCGR (hepatic beta-oxidation and basal caloric thermogenesis). By engaging glucagon receptors concurrently with incretins, it dramatically accelerates hepatic lipid clearance while eliminating ectopic liver fat.

KPV (the C-terminal 11-13 tripeptide of alpha-MSH) is actively transported intact across intestinal and mucosal epithelial borders via the apical oligopeptide transporter PepT1. Intracellularly, KPV prevents IκB-alpha phosphorylation and blocks NF-κB nuclear translocation, suppressing the transcription of inflammatory chemokines (IL-8, TNF-alpha) without systemic immunosuppression.

Directly replenishes cellular nicotinamide adenine dinucleotide (NAD+) coenzyme pools in human skeletal muscle. Stimulates mitochondrial SIRT1/SIRT3 deacetylase signaling and PARP1 DNA repair machinery, activating AKT and mTOR phosphorylation cascades that enhance muscle cellular remodeling and insulin signaling sensitivity.

Engineered as the first truly selective agonist of the Ghrelin/Growth Hormone Secretagogue Receptor 1a (GHSR-1a, EC50 = 1.3 nM). Unlike GHRP-2 or GHRP-6, it stimulates pulsatile GH release with identical maximum efficacy while demonstrating complete non-reactivity with ACTH, cortisol, prolactin, luteinizing hormone, or FSH pathways.

Epithalon (AEDG tetrapeptide) epigenetically reactivates the promoter of the human telomerase catalytic subunit (hTERT). Induces de novo telomerase enzymatic activity in normal somatic human fibroblasts, adding hexanucleotide (TTAGGG)n repeats to chromosomal ends, delaying cellular senescence, and overcoming the classical Hayflick division barrier.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) crosses blood-brain barriers and induces rapid transcription of Brain-Derived Neurotrophic Factor (BDNF) and its high-affinity tyrosine kinase receptor TrkB in hippocampal CA1/dentate gyrus neurons. Suppresses glutamate-induced excitotoxic apoptosis, enhances cholinergic neurotransmission, and elevates synaptic neuroplasticity.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) functions as an allosteric modulator of GABA-A receptors, enhancing chloride channel affinity without binding the sedative benzodiazepine sub-site. Simultaneously inhibits carboxypeptidase and neutral endopeptidase enkephalinases, prolonging natural opioid peptide stability and modulating monoamine turnover.

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the specific binding complex between active p53 and FOXO4 in senescent cells. By releasing p53 from FOXO4 nuclear sequestration, p53 relocates to the mitochondrial outer membrane, triggering caspase-3/7 and Cytochrome C mediated apoptosis exclusively in senescent cells while leaving healthy non-senescent cells completely unharmed.

Reproduces the isolated C-terminal domain (residues 177-191) of human growth hormone with a stabilizing disulfide bond. Selectively stimulates beta-3 adrenergic pathways, triggering hormone-sensitive lipase (HSL) while inhibiting acetyl-CoA carboxylase. Because it lacks the N-terminal somatogenic domain, it exhibits zero affinity for human GH receptors, completely avoiding diabetogenic hyperglycemia or insulin resistance.

Sermorelin represents the shortest fully active sequence (first 29 amino acids) of endogenous Growth Hormone-Releasing Hormone. Binds to GHRH receptors on somatotroph cells, stimulating cyclic AMP synthesis and triggering natural secretory granules. Crucially, the GH pulse amplitude is bounded by hypothalamic somatostatin feedback, preventing pituitary receptor desensitization or excessive IGF-1 elevation.

Semaglutide possesses 94% structural homology to native human GLP-1 with an albumin-binding C18 di-acid chain that prolongs in-vivo half-life to 165 hours. Activates GLP-1 receptors in the pancreatic islets to enhance glucose-dependent insulin secretion, suppresses post-meal glucagon surge, slows gastric emptying rates, and directly signals hypothalamic POMC/CART satiety circuits.

LL-37 is an amphipathic alpha-helical host defense peptide. Disrupts bacterial phospholipid bilayers via toroidal pore formation across Gram-positive and Gram-negative species. In mammalian tissue, it engages Formyl Peptide Receptor-Like 1 (FPRL-1) and transactivates EGFR, stimulating endothelial cell proliferation, vessel branching, and accelerated dermal barrier re-epithelialization.